Metformin associates with aggressive features of endometrial cancer in women with type 2 diabetes
Urpilainen, Elina; Arima, Reetta; Karihtala, Peeter; Puistola, Ulla; Ahtikoski, Anne (2021-01-30)
URPILAINEN, E., ARIMA, R., KARIHTALA, P., PUISTOLA, U., & AHTIKOSKI, A. (2021). Metformin Associates With Aggressive Features of Endometrial Cancer in Women With Type 2 Diabetes. Anticancer Research, 41(2), 821–828. https://doi.org/10.21873/anticanres.14834
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. Published in this repository with the kind permission of the publisher.
https://rightsstatements.org/vocab/InC/1.0/
https://urn.fi/URN:NBN:fi-fe202102043724
Tiivistelmä
Abstract
Background/Aim:Preclinical studies on metformin use and endometrial cancer have been promising but epidemiological studies have reported variable results. This study aimed to assess if metformin use is associated with endometrial cancer aggressiveness and survival in women with type 2 diabetes (T2D).
Patients and methods:This retrospective hospital-based cohort consisted of women with T2D who were treated for endometrial cancer at the Oulu University Hospital, Finland, between 2007 and 2014.
Results:The sample size was 121 patients: 58 metformin users and 63 metformin non-users. Intriguingly, type 2 histology, deep myometrial invasion and the presence of lymphovascular invasion were more common in the metformin user group. However, metformin use showed no association with overall survival and progression-free survival.
Conclusion:Metformin use was associated with poorer prognostic factors in endometrial cancer patients with T2D.
Kokoelmat
- Avoin saatavuus [38865]